Serum Paraoxonase with HDL-C as a predictor of atherosclerosis in patients of Chronic Kidney Disease

Sridevi, Chaganti; Sowjanya, Uvpu; Selvi, Valeria; Rajakumari, Dmm; Babu, K. Sridhar

doi:10.51248/.v40i4.313

Biomedicine

2021

DOI: 10.51248/.v40i4.313

|View full text |Cite

Serum Paraoxonase with HDL-C as a predictor of atherosclerosis in patients of Chronic Kidney Disease

Chaganti Sridevi¹,

Uvpu Sowjanya²,

Valeria Selvi³

et al.

Abstract: Introduction and Aim: CKD (Chronic Kidney Disease) is a problem in health care spread all over the world with adverse consequences. CKD is associated with premature atherosclerosis and increased morbidity and mortality due to cardiovascular complications. Hypertriglyceridemia is a commonly seen lipid abnormality in CKD patients. PON-1 (Paraoxanase-1) is a glycoprotein synthesized in the liver and is released into the blood, where it links with HDL. This study was undertaken to find out the relation between PON… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Paraoxonase 1 and Chronic Kidney Disease: A Meta-Analysis

Watanabe

Kotani

Gugliucci

2023

JCM

View full text Add to dashboard Cite

Oxidative stress is known to be associated with the pathophysiology of chronic kidney disease (CKD). Paraoxonase 1 (PON1) is an antioxidant enzyme that has been proposed as a biomarker for CKD. While several studies have reported an association between serum PON1 activity and CKD, consensus based on systematically analyzed data remains necessary. We set out to conduct a meta-analysis of literature on PON1 in CKD. Electronic databases, such as MEDLINE, Embase and CENTRAL, were searched for available studies on PON1 activity in patients with CKD (without dialysis) as published before December 2022. A random-effects meta-analysis was performed. In total, 24 studies (22 studies on paraoxonase and 11 on arylesterase activity) were eligibly identified. Patients with CKD showed a lower activity of paraoxonase (standard mean difference [SMD], −1.72; 95% confidence interval [CI], −2.15 to −1.29) and arylesterase (SMD, −2.60; 95%CI, −3.96 to −1.24) than healthy controls. In the subgroup analyses, paraoxonase activity was lower in chronic kidney failure (CKF), an advanced stage of CKD, than in non-CKF. In summary, PON1 activity is low in patients with CKD, suggesting that the antioxidant defense by PON1 is impaired in CKD. The decrease in enzyme activity is pronounced in advanced CKD showing some variability depending on the substrate employed to measure PON1 activity. Further studies are warranted.

show abstract

Paraoxonase 1 and Chronic Kidney Disease: A Meta-Analysis

Watanabe

Kotani

Gugliucci

2023

JCM

View full text Add to dashboard Cite

show abstract

Paraoxonase 1 Activity and Renal Replacement Therapy for Chronic Renal Failure: A Meta-Analysis

Watanabe

Kotani

Iwazu

et al. 2023

JCM

View full text Add to dashboard Cite

Chronic renal failure (CRF) is associated with the development of cardiovascular disease (CVD). Paraoxonase 1 (PON1), an antioxidant enzyme, shows cardioprotective properties and has been proposed as a therapeutic marker for CRF. A systematic analysis of the literature assessing the association between PON1 activity and renal replacement therapy (RRT) of CRF is currently lacking. Therefore, we set out to perform a meta-analysis of the available data on PON1 in RRT of CRF. We searched three electronic databases for studies on PON1 activity in CRF patients with RRT such as hemodialysis (HD), peritoneal dialysis (PD), or renal transplantation (RTx), published before June 2023. A random-effects and network meta-analysis were performed. A total of 53 studies were eligibly identified. Compared to CRF patients without RRT, RTx patients had higher paraoxonase activity (standard mean difference (SMD), 1.76, 95% confidence interval (CI), 0.76–2.75), followed by HD (SMD, 0.73; 95% CI, 0.02–1.45) and PD patients. Likewise, RTx patients had higher arylesterase activity (SMD, 1.84, 95% CI, 0.18–3.50), followed by HD and PD patients. Also, paraoxonase activity was increased after HD (SMD, 0.59, 95% CI, 0.16–1.03). In conclusion, the overall data demonstrated that PON1 activity is higher in CRF patients with RRT, particularly RTx, followed by that of HD and PD. Measuring PON1 activity can also be included to the paraclinical toolbox for the management of RRT, in addition to the understanding of CRF-related pathophysiology. Regarding the selection of RRT types and their potential to prevent CVD, more research is required.

show abstract

Estimation of antioxidant enzymes in hemodialysis patients

Majeed,

Jewad,

Al Atbee

2024

Egyptian Pharmaceutical Journal

View full text Add to dashboard Cite

Background Oxidative stress in hemodialysis (HD) is a critical concern in the management of patients. HD, a life-sustaining renal replacement therapy, exposes individuals to various factors that promote the production of harmful reactive oxygen species within the body. These reactive oxygen species, including free radicals, can overwhelm the body’s antioxidant defenses, leading to oxidative stress. Objective This study aimed to evaluate the activities of superoxide dismutase (SOD), glutathione peroxides (GPx) and catalase (CAT), and serum malondialdehyde (MDA) levels with dyslipidemia in HD patients and compare them with control groups. Patients and methods The case–control study was conducted on 75 patients undergoing HD and 75 age-matched healthy controls. Oxidative stress markers include CAT, SOD, GPx, and MDA. Serum electrolytes including potassium ion (K+), phosphate (PO4), calcium (Ca+), urea, and creatinine (Cr) were measured for each group. Results Our results show a significant difference between patients and the control group in each of the oxidative stress markers, which are CAT, GPx, and SOD, showing a decrease that is statistically significant in patients in comparison to the controls. The level of MDA shows an increase that is statistically significant in patients in comparison to the controls. Serum electrolyte levels, which are K+, PO4, urea, and Cr, show a statistically significant increase in patients in comparison to the controls. Ca+ shows a decrease that is statistically significant in patients in comparison to the controls. Conclusions From the results, we could conclude that oxidative stress plays a role in HD patients and can affect the management of end-stage renal failure patients.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Serum Paraoxonase with HDL-C as a predictor of atherosclerosis in patients of Chronic Kidney Disease

Cited by 3 publications

References 22 publications

Paraoxonase 1 and Chronic Kidney Disease: A Meta-Analysis

Paraoxonase 1 and Chronic Kidney Disease: A Meta-Analysis

Paraoxonase 1 Activity and Renal Replacement Therapy for Chronic Renal Failure: A Meta-Analysis

Estimation of antioxidant enzymes in hemodialysis patients

Contact Info

Product

Resources

About